Drug-Induced Renal Calculi: Epidemiology, Prevention and Management

Drugs

Volumn 64, Issue 3, 2004, Pages 245-275

  Daudon, Michel ^a   Jungers, Paul ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ANTACID AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BENZBROMARONE; BENZIODARONE; CALCIUM; CARBONATE DEHYDRATASE INHIBITOR; FUROSEMIDE; GUAIFENESIN; INDINAVIR; LAXATIVE; METHOTREXATE; NELFINAVIR; NIMESULIDE; PIRIDOXILATE; PRIMIDONE; PROTEINASE INHIBITOR; PURINE DERIVATIVE; QUINISOCAINE; SILICATE; SULFADIAZINE; SULFONAMIDE; TIENILIC ACID; TRIAMTERENE; UNINDEXED DRUG; URICOSURIC AGENT; VITAMIN D;

ALKALINIZATION; ANALYTIC METHOD; CRYSTAL; CRYSTALLIZATION; CRYSTALLURIA; DISEASE COURSE; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFRARED SPECTROSCOPY; KIDNEY DISEASE; LONG TERM CARE; METABOLISM; METABOLITE; NEPHROLITHIASIS; PARAMETER; PATIENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STONE FORMATION; TREATMENT INDICATION; URINARY EXCRETION; URINE PH; URINE VOLUME; UROLITHIASIS; VITAMIN SUPPLEMENTATION; X RAY DIFFRACTION;

HUMANS; KIDNEY CALCULI; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1442357702     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464030-00003     Document Type: Review

References (330)

1. Antopol W, Robinson H. Urolithiasis and renal pathology after administration of sulfapyridine. Proc Soc Exp Biol Med 1939; 40: 428-39
2. Barnes RW, Kawaichi GK. Factors influencing the formation of sulfonamide urinary concretions. J Urol 1943; 49: 324-30
3. Sulfamidothérapie intestinale. In: Abaza A. Acquisitions médicales récentes dans les pays alliés. Paris: Doin & Cie, 1946: 260-83
4. Lawrence JS, Francis J, Sorsby A, et al. The sulphonamides and antibiotics in man and animals. London: Lewis HK & Co Ltd, 1953
5. Lehr D. Clinical toxicity of sulfonamides. Ann N Y Acad Sci 1957; 69: 417-47
6. Curtis JR. Drug-induced renal disease. Drugs 1979; 18 (5): 377-91
7. Daudon M, Protat MF, Réveillaud RJ. Detection and diagnosis of drug-induced urinary calculi [in French]. Ann Biol Clin (Paris) 1983; 41 (4): 239-49
8. Réveillaud RJ, Daudon M. Drug-induced urinary lithiasis [in French]. Presse Med 1983; 12 (38): 2389-92
9. Cifuentes Delatte L. Composicion y estructura de los calculos renales. Madrid: Salvat, 1984
10. Daudon M, Réveillaud RJ. Drug nephrolithiasis: an unrecognized and underestimated pathology. In: Schwille PO, Smith LH, Robertson WG, et al., editors. Urolithiasis and related clinical Research. New York: Plenum Press, 1985: 371-4
11. Réveillaud RJ, Daudon M. Les lithiases urinaires médicamenteuses. Semin Uro-Nephrol 1986; 12: 14-39
12. Rapado A, Traba ML, Caycho C, et al. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib Nephrol 1987; 58: 25-9
13. Daudon M, Estepa L. Drug induced lithiases [in French]. Presse Med 1998; 27 (14): 675-83
14. Daudon M. Drug-induced urinary calculi in 1999 [in French]. Prog Urol 1999; 9 (6): 1023-33
15. Watson RA, Ettinger B, Deshon Jr GE, et al. Triamterene stone: advantage of crystallographic analysis. Urology 1981; 18 (3): 238-40
16. Daudon M, Bader CA, Jungers P. Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc 1993; 7: 1081-106
17. Nguyen Quy D, Daudon M. Infrared and raman spectra of calculi. Paris: Elsevier, 1997
18. Daudon M, Réveillaud RJ. Drug-induced crystalluria: myths and realities [in French]. Ann Biol Clin 1986; 44 (1): 25-34
19. Daudon M. Méthodes d'analyse des calculs et des cristaux urinaires: classification morpho-constitutionnelle des calculs. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences, 1989: 35-113
20. Perazella MA. Crystal-induced acute renal failure. Am J Med 1999 Apr; 106: 459-65
21. Gagnon RF, Tsoukas CM, Watters AK. Light microscopy of indinavir urinary crystals [letter]. Ann Intern Med 1998; 128 (4): 321
22. Cohen-Solal F, Abdelmoula J, Hoarau MP, et al. Urinary lithiasis of medical origin [in French]. Therapie 2001; 56 (6): 743-50
23. Daudon M, Réveillaud RJ, Normand M, et al. Piridoxilate-induced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis. J Urol 1987; 138 (2): 258-61
24. Ettinger B, Oldroyd NO, Sorgel F. Triamterene nephrolithiasis. JAMA 1980; 244 (21): 2443-5
25. Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem 1986; 24: 767-8
26. Ettinger B, Weil E, Mandel NS, et al. Triamterene-induced nephrolithiasis. Ann Intern Med 1979; 91 (5): 745-6
27. Socolow EL. Triamterene-induced nephrolithiasis [letter]. Ann Intern Med 1980; 92 (3): 437
28. Baudin S, Rodrigue H. Drug induced nephrolithiasis: observation of an oxalate and hydroxylated triamterene stone [in French]. Néphrologie 1980; 1 (4): 183-5
29. Gault MH, Snedden W, Taor RE, et al. Triamterene urolithiasis. CMAJ 1981; 124 (12): 1556-7
30. Grunberg RW, Silberg SJ. Triamterene-induced nephrolithiasis. JAMA 1981; 245 (24): 2494-5
31. Daudon M, Protat MF, Réveillaud RJ. Triamterene and renal calculi [in French]. Nephrologie 1982; 3 (3): 119-23
32. Moesch C, Rincé M, Raby C, et al. Analysis of triamterene induced renal stones [in French]. J Pharm Clin 1989; 18: 87-95
33. Carey RA, Beg MM, McNally CF, et al. Triamterene and renal lithiasis: a review. Clin Ther 1984; 6 (3): 302-9
34. Ettinger B. Risk of kidney stones [letter]. JAMA 1982; 248 (16): 1971
35. Woolfson RG, Mansell MA. Does triamterene cause renal calculi? BMJ 1991 Nov; 303: 1217-8
36. Carr MC, Prien Jr EL, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. J Urol 1990; 144 (6): 1339-40
37. Sorgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol 1985; 134 (5): 871-3
38. Sabot JF, Bernard P, Pinatel H, et al. Analysis of urinary calculi containing triamterene: presence of a glucuronic metabolite. Anal Lett 1996, 27
39. Pruitt A, Winkel J, Dayton P. Variations in the fate of triamterene. Clin Pharmacol Ther 1977; 21: 610-9
40. Sorgel F, Ettinger B, Benet LZ. Metabolic fate and solubility of triamterene: not an explanation for triamterene nephrolithiasis. J Pharm Sci 1986; 75 (2): 129-32
41. Fairley KF, Birch DF, Haines I. Abnormal urinary sediment in patients on triamterene. Lancet 1983; I: 421-2
42. Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylindruria: clinical and experimental studies. Clin Nephrol 1986; 26: 169-73
43. Farge D, Turner MW, Roy DR, et al. Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition. Am J Kidney Dis 1986; 8 (6): 445-9
44. Roy LF, Villeneuve JP, Dumont A, et al. Irreversible renal failure associated with triamterene. Am J Nephrol 1991; 11: 486-8
45. Jick H, Dinan BJ, Hunter JR. Triamterene and renal stones. J Urol 1982; 127 (2): 224-5
46. Ettinger B. Excretion of triamterene and its metabolite in triamterene stone patients. J Clin Pharmacol 1985; 25 (5): 365-8
47. Kau S. Handling of triamterene by the isolated perfused rat kidney. J Pharmacol Exp Ther 1978; 206: 701-9
48. Sica DA, Gehr TW. Triamterene and the kidney. Nephron 1989; 51 (4): 454-61
49. Jungers P, Daudon M. Formes cliniques de la lithiase urinaire: lithiases médicamenteuses. In: Jungers P, Daudon M, Le Duc A, editors. Lithiase urinaire. Paris: Flammarion Médecine-Sciences, 1989: 408-16
50. White DJ, Nancollas GH. Triamterene and renal stone formation. J Urol 1982; 127 (3): 593-7
51. Werness PG, Bergert JH, Smith LH. Triamterene urolithiasis: solubility, pk, effect on crystal formation, and matrix binding of triamterene and its metabolites. J Lab Clin Med 1982; 99 (2): 254-62
52. Lynn K, Bailey R, Swainson C, et al. Renal failure with potassium-sparing diuretics. N Z Med J 1985; 98: 629-33
53. Favre L, Glasson P, Valotton M. Reversible acute renal failure from combined triamterene and indomethacin. Ann Intern Med 1982; 96: 317-20
54. Weinberg M, Quigg R, Salant D, et al. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40: 216-8
55. Estepa-Maurice L, Hennequin C, Marfisi C, et al. Fourier transform infrared microscopy identification of crystal deposits in tissues: clinical importance in various pathologies. Am J Clin Pathol 1996; 105: 576-82
56. Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet 1985; II (8446): 73-5
57. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124 (12): 1086-8
58. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277 (2): 145-53
59. European Agency for the Evaluation of Medicinal Products. Commission decision of 4 October 1996 granting the marketing authorization for the medicinal product for human use, 'CRIXIVAN® - Indinavir'. London: European Agency for the Evaluation of Medicinal Products, 1996
60. Merck & Co. Crixivan (indinavir sulphate) [Product monograph]. West Point (PA): Merck & Co., 1997
61. Herman JS, Ives NJ, Nelson M, et al. Incidence and risk factors for the development of indinavir-associated renal complications. J Antimicrob Chemother 2001; 48 (3): 355-60
62. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-25
63. Hermieu JF, Prevot MH, Ravery V, et al. Nephritic colic due to indinavir [in French]. Presse Med 1998; 27 (10): 465-7
64. Piroth L, Grappin M, Waldner A, et al. Discontinuation of protease inhibitors due to intolerance: a longitudinal study in 309 HIV-1 positive patients [in French]. Presse Med 1999; 28 (8): 381-7
65. Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS 1998; 12 (18): F249-54
66. Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999; 161 (4): 1082-4
67. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133 (1): 35-9
68. Saltel E, Angel JB, Futter NG, et al. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 2000; 164 (6): 1895-7
69. Hermieu J, Prevot M, Ravery V, et al. Urolithiasis and the protease inhibitor indinavir. Eur Urol 1999; 35 (3): 239-41
70. Gentle DL, Stoller ML, Jarrett TW, et al. Protease inhibitor-induced urolithiasis. Urology 1997; 50 (4): 508-11
71. Sundaram CP, Saltzman B. Urolithiasis associated with protease inhibitors. J Endourol 1999; 13 (4): 309-12
72. Kohan AD, Armenakas NA, Fracchia JA. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol 1999; 161 (6): 1765-8
73. Blake SP, McNicholas MMJ, Raptopoulos V. Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy. AJR Am J Roentgenol 1998; 171 (3): 717-20
74. Schwartz BF, Schenkman N, Armenakas NA, et al. Imaging characteristics of indinavir calculi. J Urol 1999; 161 (4): 1085-7
75. Kopp JB. Renal dysfunction in HIV-1-infected patients. Curr Infect Dis Rep 2002; 4 (5): 449-60
76. Kopp JB, Falloon J, Fili A, et al. Indinavir-associated with interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002; 34 (8): 1122-8
77. Van Glabeke E, Conort P, Chartier-Kastler E, et al. Treatment of complicated renal colic in patients treated with indinavir: value of double J stents [in French]. Prog Urol 1999; 9 (3): 470-3
78. Martinez E, Leguizamon M, Mallolas J, et al. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin infect Dis 1999; 29 (2): 422-5
79. Bach MC, Godofski EW. Indinavir nephrolithiasis in warm climates. J AIDS Hum Pathol 1997; 14: 296-7
80. Tashima KT, Horowitz J, Rosen S. Indinavir nephropathy. N Engl J Med 1997; 336: 138-40
81. van Rossum AM, Dieleman JP, Fraaij PL, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS 2001; 15 (13): 1745-7
82. Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001; 38 (4): E23
83. Berns JS, Cohen RM, Silverman M, et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997; 30 (4): 558-60
84. Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998; 13 (3): 750-3
85. Grabe DW, Eisele G, Miller C, et al. Indinavir-induced nephropathy. Clin Nephrol 1999; 51 (3): 181-3
86. Jaradat M, Phillips C, Yum MN, et al. Acute tubulointerstitial nephritis attributable to indinavir therapy [letter]. Am J Kidney Dis 2000; 35 (4): E16
87. Anglicheau D, Duvic C, Nedelec G. Sudden anuria due to indinavir crystalluria. Nephron 2000; 86 (3): 364-5
88. Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000; 54 (4): 261-70
89. Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol 1998; 50: 194-6
90. van Rossum AM, Dieleman JP, Fraaij PL, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir [letter]. Pediatrics 2002; 110 (2 Pt 1): e19
91. Daudon M, Estepa L, Viard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997; 349 (9061): 1294-5
92. Balani SH, Arison BH, Mathai L, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995; 23: 266-70
93. Chen IW, Vastag KJ, Lin JH. High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J Chromatogr B Biomed Appl 1995; 672: 111-7
94. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42 (2): 332-8
95. Hortin GL, King C, Miller KD, et al. Detection of indinavir crystals in urine: dependence on method of analysis. Arch Pathol Lab Med 2000; 124 (2): 246-50
96. Rickerts V, Kober A, Stille W. Kristallurie und Nephrolithiasis bei Therapie mit dem Protease-Inhibitor Indinavir [letter]. Dtsch Med Wochenschr 1997; 122 (24): 803
97. Gagnon RF, Tecimer SN, Watters AK, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000; 36 (3): 507-15
98. Daudon M, Estepa L, Viard JP, et al. Indinavir crystalluria in HIV-positive patients treated with indinavir sulfate. In: Rodgers AL, Hibbert BE, Hess B, et al., editors. Urolithiasis 2000. Vol. I. Rondebosh: University of Cape Town, 2000: 335-7
99. Daudon M, Estepa L, Viard JP, et al. Épidémiologie et facteurs de risque des complications lithiasiques de l'indinavir. Feuill Biol 2001; 42 (242): 31-4
100. Famularo G, Di Toro S, Moretti S, et al. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000; 34 (12): 1414-8
101. Daudon M, Estepa L, Kebede M, et al. Urinary calculi and crystalluria in HIV+ patients treated with indinavir sulfate [in French]. Presse Med 1997; 26 (34): 1612-5
102. Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 1999; 340 (5): 392-3
103. Brodie SB, Keller MJ, Ewenstein BM, et al. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998; 12 (18): 2433-7
104. Ascher DP, Lucy MD. Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection. Ann Pharmacother 1997; 31 (10): 1146-9
105. Malavaud B, Dinh B, Bonnet E, et al. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 2000; 5 (1): 3-5
106. Dieleman JP, Sturkenboom MC, Jambroes M, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Arch Intern Med 2002; 162 (13): 1493-501
107. Meraviglia P, Angeli E, Del Sorbo F, et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS 2002; 16 (15): 2089-93
108. Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13 (4): 473-8
109. Rebassa Llull MJ, Conte Visus A, Grases Freixedas F, et al. Anuria in HIV+ patients treated with indinavir [in Spanish]. Arch Esp Urol 2000; 53 (8): 719-21
110. Kalaitzis C, Dimitriadis G, Tsatidis T, et al. Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients. Int Urol Nephrol 2002; 34 (1): 13-5
111. Wu DS, Stoller ML. Indinavir urolithiasis. Curr Opin Urol 2000; 10 (6): 557-61
112. Grases F, Costa-Bauza A, Garcia-Gonzalez R, et al. Indinavir crystallization and urolithiasis. Int Urol Nephrol 1999; 31 (1): 23-9
113. Verdon R, Daudon M, Albessard F, et al. Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus. Clin Infect Dis 2002; 35 (5): e57-9
114. Burger DM, Hugen PW, Aamoutse RE, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001; 26 (3): 218-24
115. Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol 2002; 167 (3): 1384-5
116. Trolliet P, Dijoud F, Cotte L, et al. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am J Nephrol 1995; 15: 256-9
117. Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis 1998; 32 (3): 392-400
118. Peterslund NA, Larsen ML, Mygind H. Acyclovir crystalluria. Scand J Infect Dis 1988; 20 (2): 225-8
119. Sawyer MH, Webb DE, Balow JE, et al. Acyclovir-induced renal failure: clinical course and histology. Am J Med 1988; 84 (6): 1067-71
120. Bianchetti MG, Roduit C, Oetliker OH. Acyclovir-induced renal failure: course and risk factors. Pediatr Nephrol 1991; 5: 238-9
121. Becker BN, Fall P, Hall C, et al. Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature. Am J Kidney Dis 1993; 22: 611-5
122. Fogazzi GB. Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transplant 1996; 11 (2): 379-87
123. Newman HR, Shleser IH. Sulfonamide renal calculus. J Urol 1942; 47: 258-9
124. Schreiner GE, Maher JF. Toxic nephropathy. Am J Med 1965; 38: 409-49
125. Albala DM, Prien Jr EL, Galal HA. Urolithiasis as a hazard of sulfonamide therapy. J Endourol 1994; 8 (6): 401-3
126. Diaz F, Collazos J, Mayo J, et al. Sulfadiazine-induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann Pharmacother 1996; 30 (1): 41-2
127. Goadsby PJ, Donaghy AJ, Lloyd AR, et al. Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure. Ann Intern Med 1987; 107 (5): 783-4
128. Sahai J, Heimberger T, Collins K, et al. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder. Am J Med 1988; 84 (4): 791-2
129. Christin S, Baumelou A, Bahri S, et al. Acute renal failure due to sulfadiazine in patients with AIDS. Nephron 1990; 55 (2): 233-4
130. Hein R, Brunkhorst R, Thon WF, et al. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clin Nephrol 1993; 39 (5): 254-6
131. Kronawitter U, Jakob K, Zoller WG, et al. Acute kidney failure caused by sulfadiazine stones: a complication of the therapy of toxoplasmosis in AIDS [in German]. Dtsch Med Wochenschr 1993; 118 (46): 1683-6
132. Marques LP, Madeira EP, Santos OR. Renal alterations induced by sulfadiazine therapy in an AIDS patients. Clin Nephrol 1994; 42 (1): 68-9
133. Furrer H, von Overbeck J, Jaeger P, et al. Sulfadiazine nephrolithiasis and nephropathy [in German]. Schweiz Med Wochenschr 1994; 124 (46): 2100-5
134. Potter JL, Kofron WG. Sulfadiazine/N4-acetylsulfadiazine crystalluria in a patient with the acquired immune deficiency syndrome (AIDS). Clin Chim Acta 1994; 230 (2): 221-4
135. Farina LA, Palou Redorta J, Chechile Toniolo G. Reversible acute renal failure due to sulfonamide-induced lithiasis in an AIDS patient. Arch Esp Urol 1995; 48 (4): 418-9
136. Rodriguez-Carballeira M, Casagran A, More J, et al. Acute renal insufficiency caused by a sulfadiazine in a patient with cerebral toxoplasmosis and AIDS [in Spanish]. Enferm Infecc Microbiol Clin 1996; 14 (2): 125-7
137. Crespo M, Quereda C, Pascual J, et al. Patterns of sulfadiazine acute nephrotoxicity. Clin Nephrol 2000; 54 (1): 68-72
138. Sillar DB, Kleinig D. Sulphur calculi from ingestion of sulphasalazine. Br J Urol 1993; 71 (6): 750-1
139. Erturk E, Casemento JB, Guertin KR, et al. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol 1994; 151 (6): 1605-6
140. Yanagisawa R, Kamijo T, Nagase Y. A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis [in Japanese]. Nippon Hinyokika Gakkai Zasshi 1999; 90 (3): 462-5
141. Russinko PJ, Agarwal S, Choi MJ, et al. Obstructive nephropathy secondary to sulfasalazine calculi. Urology 2003; 62 (4): 748
142. Dorfman LE, Smith JP. Sulfonamide crystalluria: a forgotten disease. J Urol 1970; 104 (3): 482-3
143. Daudon M, Protat MF, Réveillaud RJ, et al. Study of spontaneous crystalluria by infrared spectroscopy: search for correlations between crystals, calculi, bacteria and the sex of the patients [in French]. Ann Biol Clin (Paris) 1983; 41: 199-207
144. Siegel WH. Unusual complication of therapy with sulfamethoxazole- trimethoprim. J Urol 1977; 117 (3): 397
145. Karcher G, Tammen H, Martin C. Healing of a chronic therapy-resistant urinary tract infection, complicated by bladder calculi and bladder inflow obstruction with Bactrim. Case report [in German]. Med Welt 1972; 23 (39): 1363-4
146. Bülow H, Klee WE, Hotzel A, et al. Zur Frage einer Harnsteinbildung nach Trimethoprim Sulfamethoxazol-Therapie. Fortsch Urol Nephrol 1977; 9: 116-9
147. Bulkova T, Kladensky J, Pacik D, et al. Drug-induced urolithiasis caused by N4-acetylsulfamethoxazole (Biseptol) and oxolinic acid (Desurol) [in Czech]. Rozhl Chir 1992; 71 (11): 615-23
148. Rincé M, Dudognon P, Moesch C, et al. Urinary lithiasis induced by sulfamethoxazole in a patient with tetraplegia: case report. Paraplegia 1992; 30 (10): 750-1
149. Otto H, Allesch V. Urinary concrements due to long-term sulfonamides [in German]. Urologe 1969; 8 (4): 202-4
150. Neal Jr MP. General case of the day. Sulfonamide crystallization in nonalkalinized urine. Radiographies 1988; 8 (5): 993-6
151. Whiting F, Connell R, Forman SA. Silica urolithiasis in beef cattle: the incidence on different rations and on range. Can J Comp Med Vet Sci 1958; 22: 332-7
152. Daudon M, Estepa L, Labro B, et al. Infrared analysis of urinary calculi from animals [in French]. Eurobiol 1998; 236: 243-55
153. Hammarsten G, Helldorff I, Magnusson W, et al. Dubbelsidiga njurstenar av kiselsyra efter bruk av silikathaltigt antacidum. Svensk Lakartiduing 1953; 50: 1242-6
154. Hammarsten G. Terapi-inducerade urinvOagskonkrement. Opusc Med 1958; 3 (1): 19-22
155. Herman JR, Goldberg AS. New type of urinary calculus caused by antacid therapy. JAMA 1960 Oct; 174: 1206-7
156. Lagergren C. Development of silica calculi after oral administration of magnesium trisilicate. J Urol 1962; 87 (6): 994-6
157. Lipworth E, Bloomberg BM, Reid FP. Urinary calculi containing silica: a case report. S Afr Med J 1964; 50 (1): 50-1
158. Joekes AM, Rose GA, Sutor J. Multiple renal silica calculi. BMJ 1973; 1 (846): 146-7
159. Medina JA, Rodriguez J, Santos M, et al. Siliceous renal calculi in a man (11th case in the world) [in Spanish]. Rev Clin Esp 1978; 151 (5): 411-3
160. Levison DA, Crocker PR, Banim S, et al. Silica stones in the urinary bladder. Lancet 1982; I (8274): 704-5
161. Farrer JH, Rajfer J. Silicate urolithiasis. J Urol 1984; 132 (4): 739-40
162. Irisawa C, Suzuki K, Nakagawa H, et al. Silicate urolithiasis: a case report [in Japanese]. Hinyokika Kiyo 1991; 37 (3): 267-71
163. Irani J, Doré B, Bon D, et al. Silica urinary calculi: report of a case [in French]. Prog Urol 1992; 2 (2): 290-3
164. Cruz Guerra NA, Gomez Garcia MA, Lovaco Castellano F, et al. Silica urolithiasis: report of a new case [in Spanish]. Actas Urol Esp 2000; 24 (2): 202-4
165. Augusti M, Mikaelian JC, Monsaint H, et al. A silica urinary calculus secondary to the absorption of gelopectose in a child [in French]. Prog Urol 1993; 3 (5): 812-5
166. Page RC, Heffner RR, Frey A. Urinary excretion of silica in humans following oral administration of magnesium trisilicate. Am J Dig Dis 1941; 8 (1): 13-5
167. Bailey CB. Silica excretion in cattle fed a ration predisposing to silica urolithiasis: total excretion and diurnal variations. Am J Vet Res 1967; 28 (127): 1743-9
168. Gutierrez C, Padron M, Banares A, et al. Urinary retention in two male dromedaries due to silica uroliths. Zentralbl Veterinarmed A 1999; 46 (9): 523-6
169. Osborne CA, Hammer RF, Klausner JS. Canine silica urolithiasis. J Am Vet Med Assoc 1981; 178 (8): 809-13
170. Manning RA, Blaney BJ. Identification of uroliths by infrared spectroscopy. Aust Vet J 1986; 63 (12): 393-6
171. Forman SA, Whiting F, Connell R. Silica urolithiasis in beef cattle:3. chemical and physical composition of the uroliths. Can J Comp Med 1959; 23 (4): 157-62
172. Bailey CB. The precipitation of polymerized silicic acid by urine protein: a possible mechanism in the etiology of silica urolithiasis. Can J Biochem 1972; 50 (3): 305-11
173. Aldrich J, Ling GV, Ruby AL, et al. Silica-containing urinary calculi in dogs (1981-1993). J Vet Intern Med 1997; 11 (5): 288-95
174. Singh SV, Khan MF, Rahman Q. Interaction of silica with plasma proteins: in vivo studies. Toxicol Letters 1985; 28 (2-3): 89-92
175. Emerick RJ. Phosphate inhibition of protein-polysilicic acid complex formation in vitro: a factor in preventing silica urolithiasis. J Nutr 1987; 117 (11): 1924-28
176. Angwafo III FF, Daudon M, Wonkam A, et al. Pediatric urolithiasis in sub-Saharan Africa: a comparative study in two regions of Cameroon. Eur Urol 2000; 37: 106-11
177. Gault MH, Campbell NR, Aksu AE. Spurious stones. Nephron 1988; 48 (4): 274-9
178. Sabot JF, Bornet CE, Favre S, et al. The analysis of peculiar urinary (and other) calculi: an endless source of challenge. Clin Chim Acta 1999; 283 (1-2): 151-8
179. Alpaugh HB, Johnson FB. Silicon dioxide calculi in humans in the absence of silicate antacid medication. Scan Electron Microsc 1986; Pt (2): 969-72
180. Gaultier M, Bismuth C, Efthymiou ML, et al. Néphropathie tubulo-interstitielle aiguë au cours d'une intoxication par la glafénine [letter]. Nouv Presse Med 1975; 1: 3125
181. Réveillaud RJ, Daudon M, Protat MF, et al. Renal pelvis stones made of glafenic acid in two patients under prolonged treatment with analgesics (author's translation) [in French]. Nephrologie 1980; 1 (1): 3-8
182. Daudon M, Protat MF, Réveillaud RJ. Renal toxicity of glafenine in man: renal stones and acute renal failure [in French]. Ann Biol Clin (Paris) 1983; 41 (2): 105-11
183. Pasquier B, Griffa N, Heritier P, et al. Urinary calculi caused by glaphenine: role of radiology in diagnosis: apropos of a case [in French]. J Radiol 1989; 70 (6-7): 423-5
184. Moesch C, Daudon M, Leymarie J, et al. Glaphenine-containing gallstones. Eur J Chem Clin Biochem 1993; 31 (5): 329-33
185. Daudon M, Moesch C, Marty L, et al. Antrafénine: calculs urinaires et cristalluries. Thérapie 1986; 41: 499-504
186. Moesch C, Rincé M, Raby C, et al. Identification d'un métabolite de la floctafénine dans un calcul urinaire. Ann Biol Clin (Paris) 1987; 45: 546-50
187. Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med 1975; 292 (12): 626-7
188. Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complication of allopurinol therapy. N Engl J Med 1969; 280 (8): 426-7
189. Sperling O, Brosh S, Boer P, et al. Urinary xanthine stones in an allopurinol-treated gouty patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. Isr J Med Sci 1978; 14 (2): 288-92
190. Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol 1983; 130 (1): 157-9
191. Loris Pablo C, Olivan del Cacho MJ, Heras Gironella M, et al. Xanthine lithiasis in a case of Lesch-Nyhan syndrome treated with allopurinol [in Spanish]. An Esp Pediatr 1983; 19 (5): 401-4
192. Kranen S, Keough D, Gordon RB, et al. Xanthine-containing calculi during allopurinol therapy. J Urol 1985; 133 (4): 658-9
193. Oka T, Utsunomiya M, Ichikawa Y, et al. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection. Urol Int 1985; 40 (3): 138-40
194. Volpe P, Peyrottes A, Lammle M, et al. Calcul urinaire de xanthine chez un patient porteur d'un syndrome de Lesh Nyhan: a propos d'un cas. Prog Urol 1997; 7 (1): 74-7
195. Stote RM, Smith LH, Dubb JW, et al. Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy. Ann Intern Med 1980; 92 (3): 384-5
196. Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem 1987; 33 (12): 2314-6
197. Rincé C, Daudon M, Moesch C, et al. Identification of flumequine in a urinary calculus. J Clin Chem Clin Biochem 1987; 25: 313-4
198. Cifuentes I, Bellanato J, Arquillué A, et al. Presencia de acido oxolinico en un calculo renal. Arch Esp Urol 1986; 39 (5): 369-73
199. Daudon M, Réveillaud RJ, Laurence C, et al. Drug-induced oxolinic acid crystalluria and nephrolithiasis [letter]. Clin Nephrol 1987; 28 (3): 156
200. Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urol 2000; 164 (2): 438
201. Najjar MF, Rammah M, Oueslati A, et al. Apport de la spectrophotométrie infrarouge dans l'analyse des calculs urinaires. Le Biologiste 1988; 22: 215-20
202. Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant 1990; 5 (11): 974-6
203. Dulac Y, Bouissou F, Azéma C, et al. Anuria caused by urinary lithiasis induced by ceftriaxone in a 6-year-old child [in French; letter]. Presse Med 1995; 24 (19): 916
204. Feher O, Benczik A, Szabo E, et al. Renal gravel formation inducing renal insufficiency as a side-effect of ceftriaxon [in Hungarian]. Orv Hetil 1999; 140 (14): 769-71
205. de Moor RA, Egberts AC, Schroder CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999; 158 (12): 975-7
206. Mulvaney WP, Beck CW, Brown RR. Urinary phenazopyridine stones: a complication of therapy. JAMA 1972; 221: 1511-2
207. Crawford ED, Mulvaney WP. Rapid increase in calculous size: a possible hazard of phenazopyridine hydrochloride therapy in the presence of already formed stones. J Urol 1978; 119 (2): 280-1
208. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988; II (8625): 1411-3
209. Lopez AJ, O'Keefe P, Morrissey M, et al. Ceftriaxone-induced cholelithiasis. Ann Intern Med 1991; 115 (9): 712-4
210. Kearney DK, O'Donnell D. Iatrogenic gallstones: a ceftriaxone complication. Australas Radiol 1998; 42: 236-7
211. Ko CW, Sekijima JH, Lee SP. Biliary sludge. Ann Intern Med 1999; 130 Pt 1: 301-11
212. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995; 13 (6): 343-58
213. Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 1986; 32: 408-17
214. Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy 1988; 34: 256-60
215. Rippelmeyer DJ, Synhavsky A. Ciprofloxacin and allergic interstitial nephritis [letter]. Ann Intern Med 1988; 109: 170
216. Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32 (2): 75-8
217. Allon M, Lopez EJ, Min KW. Acute renal failure due to ciprofloxacin. Arch Intern Med 1990; 150: 2187-9
218. Schlüter G. Ciprofloxacin: review of potential toxicologic effects. Am J Med 1987; 82 Suppl. 4A: 91-3
219. Zupancic M, Bukovec P. Complexation of magnesium (II) with ciprofloxacin and norfloxacin. Act Pharm 1996; 46: 221-8
220. Swanson BN, Boppana VK, Vlasses PH, et al. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983; 23 (2): 284-8
221. Moesch C, Rincé M, Raby C, et al. Aminopenicillin crystalluria: identification by infrared spectrophotometry [in French]. Ann Biol Clin (Paris) 1985; 43 (3): 227-31
222. Boffa JJ, De Preneuf H, Bouadma L, et al. Acute renal failure after
223. Boursas M, Benhassine L, Kempf J, et al. Obstructive renal insufficiency caused by amoxicillin crystalluria [in French]. Ann Fr Anesth Reanim 1997; 16 (7): 908-10
224. Fogazzi GB, Cantu M, Saglimbeni L, et al. Amoxycillin, a rare but possible cause of crystalluria. Nephrol Dial Transplant 2003; 18 (1): 212-4
225. Menzi P. Furadantin-Stein in einer Ureterozele. Helvet Chir 1970; 37 (4/5): 538-40
226. MacDonald JB, MacDonald ET. Nitrofurantoin crystalluria. BMJ 1976 Oct 30; II: 1044-5
227. Pickens CL, Milliron AR, Fussner AL, et al. Abuse of guaifenesin- containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Urology 1999; 54 (1): 23-7
228. Assimos DG, Langenstroer P, Leinbach RF, et al. Guaifenesin-and ephedrine-induced stones. J Endourol 1999; 13 (9): 665-7
229. Blau JJ. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. J Urol 1998; 160 (3 Pt 1): 825
230. Powell T, Hsu FF, Turk J, et al. Ma-Huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis 1998; 32 (1): 153-9
231. Cate IV JC, Tenser R. Acute primidone overdose with massive crystalluria. Clin Toxicol 1975; 8 (4): 385-9
232. Lehmann DF. Primidone crystalluria following overdose: a report of a case and an analysis of the literature. Med Toxicol Adverse Drug Exp 1987; 2 (5): 383-7
233. Pitman SW, Frei E. Weekly methotrexate-calcium leukovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61: 695-701
234. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981; 19: 453-6
235. Garnick MB, Mayer RJ, Abelson HT. Acute renal failure associated with cancer treatment. In: Brenner BM, Lazarus JM, editors. Acute renal failure. 2nd ed. New York: Churchill Livingstone, 1988: 636-45
236. Lenk S, Brien G, Bick C. Harnsteinbildung durch Dihydrotachysterol- Uberdosierung. Z Arztl Forbild 1970; 9: 470-1
237. Taylor WH. Renal calculi and self-medication with multivitamin preparations containing vitamin D. Clin Sci 1972; 42: 515-22
238. Pak CYC. Nephrolithiasis from calcium supplementation. J Urol 1987; 137: 1212-3
239. Jones G, Hogan DB, Yent DB, et al. Prevention and management of osteoporosis: consensus statements from scientific Advisory Board of the Osteoporosis Society of Canada. 8: vitamin D metabolites and analogs in the treatment of osteoporosis. CMAJ 1996; 155: 955-61
240. Oreopoulos DG, Silverberg S. Calcium oxalate urinary-tract stones in patients on maintenance dialysis. N Engl J Med 1974; 290 (25): 1438-9
241. Caralps A, Lloveras J, Andreu J, et al. Urinary calculi in chronic dialysis patients. Lancet 1979; II (8150): 1024-5
242. Oren A, Husdan H, Chen PT, et al. Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1984; 25 (3): 534-8
243. Daudon M, Lacour B, Jungers P, et al. Urolithiasis in patients with end-stage renal failure. J Urol 1992; 147: 977-80
244. Kass M, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophtalmology 1981; 88: 261-5
245. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf 1996; 15 (6): 378-93
246. Willmore LJ. Choice and use of newer anticonvulsant drugs in older patients. Drugs Aging 2000; 17 (6): 441-52
247. Persky L, Chambers D, Potts A. Calculus formation and ureteral colic following acetazolamide therapy. JAMA 1956; 161: 1625-6
248. Barraquer J, Escribano J. Colicos renales en el curso de tratamientos con acetazolamide. Rev Clin Esp 1957; 64: 310-3
249. Parfitt AM. Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis; relationship to citrate and calcium excretion. Arch Intern Med 1969; 124 (6): 736-40
250. Pepys MB. Acetazolamide and renal stone formation [letter]. Lancet 1970; I (7651): 837
251. Parfitt AM. Acetazolamide and renal stone formation [letter]. Lancet 1970; II (7664): 153
252. Roise O, Otnes B. Acetazolamide and renal calculi [in Norwegian]. Tidsskr Nor Laegeforen 1986; 106 (1): 25-6
253. Rivalan J, Chevet D, Le Pogamp P, et al. Renal lithiasis, a logical complication of long-term treatment of glaucoma with a carbonic anhydrase inhibitor [in French]. Ann Med Interne (Paris) 1989; 140 (5): 419-20
254. Tawil R, Moxley III RT, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993; 43 (6): 1105-6
255. Ellis PP. Urinary calculi with methazolamide therapy. Doc Ophthalmol 1973; 34: 137-42
256. Carlsen J, Durcan J, Zabriskie N, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999; 117 (8): 1087-8
257. Wallace MR, MacDiarmid J, Reeder J. Exacerbation of nephrolithiasis by a carbonic anhydrase inhibitor. N Z Med J 1974; 79 (509): 687-90
258. Resor Jr SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990; 40 (11): 1677-81
259. Parikh JR, Nolan RL. Acetazolamide-induced nephrocalcinosis. Abdom Imaging 1994; 19 (5): 466-7
260. Libenson MH, Kaye EM, Rosman NP, et al. Acetazolamide and furosemide for posthemorrhagic hydrocephalus of the newborn. Pediatr Neurol 1999; 20 (3): 185-91
261. Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21: 225-8
262. Paisley KE, Tomson CR. Calcium phosphate stones during long-term acetazolamide treatment for epilepsy. Postgrad Med J 1999; 75 (885): 427-8
263. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35 (4): 241-56
264. Natsch S, Hekster YA, Keyser A, et al. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 1997; 17 (4): 228-40
265. Glauser TA. Topiramate. Epilepsia 1999; 40 Suppl. 5: S71-80
266. Saito Y, Yanagaki S, Oguni H, et al. Urolithiasis induced by combined ACTH and zonisamide treatment in a patient with startle induced epilepsy [in Japanese]. No To Hattatsu 2002; 34 (5): 415-20
267. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996; 37 Suppl. 2: S18-22
268. Markind JE. Topiramate: a new antiepileptic drug. Am J Health Syst Pharm 1998; 55 (6): 554-62
269. Takhar J, Manchanda R. Nephrolithiasis on topiramate therapy. Can J Psychiatry 2000; 45 (5): 491-3
270. Daudon M, Réveillaud RJ, Rod D, et al. Piridoxilate-induced calcium oxalate nephrolithiasis: a nation-wide epidemiologic evaluation of incidence. In: Walker VR, Sutton RAL, Cameron ECB, et al., editors. Urolithiasis. New York: Plenum Press, 1989: 677-9
271. Daudon M, Réveillaud RJ, Jungers P. Piridoxilate-associated calcium oxalate urinary calculi: a new metabolic drug-induced nephrolithiasis [letter]. Lancet 1985; I (8441): 1338
272. Wolf C, Maistre-Charransol G, Barthélémy C, et al. Iatrogenic oxalic lithiasis caused by piridoxilate [in French]. Nephrologie 1985; 6 (5): 225-7
273. Vigeral P, Kenouch S, Chauveau D, et al. Piridoxilate-associated nephrocalcinosis: a new form of chronic oxalate nephropathy. Nephrol Dial Transplant 1987; 2 (4): 275-8
274. Dequiedt P, Gosselin B, Benoit O, et al. Acute renal failure caused by acute oxalosis after massive ingestion of piridoxilate [in French]. Nephrologie 1985; 6 (5): 228-30
275. Mousson C, Justrabo E, Rifle G, et al. Piridoxilate-induced oxalate nephropathy can lead to end-stage renal failure. Nephron 1993; 63 (1): 104-6
276. Hufnagle KG, Khan SN, Penn D, et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 1982; 70 (3): 360-3
277. Venkataraman PS, Han BK, Tsang RC, et al. Secondary hyperparathyroidism and bone disease in infants receiving long-termfurosemide therapy. Am J Dis Child 1983; 137 (12): 1157-61
278. Glasier CM, Stoddard RA, Ackerman Jr NB, et al. Nephrolithiasis in infants: association with chronic furosemide therapy. Am J Roentgenol 1983; 140 (1): 107-8
279. Noe HN, Bryant JF, Roy III S, et al. Urolithiasis in pre-term neonates associated with furosemide therapy. J Urol 1984; 132 (1): 93-4
280. Gilsanz V, Fernal W, Reid BS, et al. Nephrolithiasis in premature infants. Radiology 1985; 154 (1): 107-10
281. Myracle MR, McGahan JP, Goetzman BW, et al. Ultrasound diagnosis of renal calcification in infants on chronic furosemide therapy. J Clin Ultrasound 1986; 14 (4): 281-7
282. Ezzedeen F, Adelman RD, Ahlfors CE. Renal calcification in preterm infants: pathophysiology and long-term sequelae. J Pediatr 1988; 113 (3): 532-9
283. Itami N, Kawaguti M, Akutsu Y, et al. Renal calcifications in preterm infants [letter]. J Pediatr 1989; 114 (6): 1068
284. Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr 1994; 125 (1): 149-51
285. Blickman JG, Herrin JT, Cleveland RH, et al. Coexisting nephrolithiasis and cholelithiasis in premature infants. Pediatr Radiol 1991; 21 (5): 363-4
286. Alon US. Nephrocalcinosis. Curr Opin Pediatr 1997; 9 (2): 160-5
287. Saarela T, Lanning P, Koivisto M, et al. Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up. Eur J Pediatr 1999; 158: 668-72
288. Kim YG, Kim B, Kim MK, et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant 2001; 16: 2303-9
289. Levine DZ, Roy D, Tolnai G, et al. Chloride depletion and nephrocalcinosis. Am J Physiol 1974; 227: 878-83
290. Sidhu H, Hoppe B, Hesse A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998; 352: 1026-9
291. Sidhu H, Schmidt ME, Cornelius JG, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999; 10: S334-40
292. Hokama S, Honma Y, Toma C, et al. Oxalate-degrading Enterococcus faecalis. Microbiol Immunol 2000; 44: 235-40
293. Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001; 60: 1097-105
294. Golematis B, Hatzitheofilou C, Dreiling DA, et al. The incidence of urolithiasis in pepticulcer patients. Am J Gastroenterol 1977; 68: 367-71
295. Robson RH, Heading RC. Obsolete but dangerous antacid preparations. Postgrad Med J 1978; 54: 36-7
296. Bloom WK, Flinchum D. Osteomalacia with pseudofractures caused by the ingestion of aluminum hydroxyde. JAMA 1960; 174: 1327-30
297. Dent CE, Winter CS. Osteomalacia due to phosphate depletion from excess aluminum hydroxide ingestion. BMJ 1974; 1: 551-2
298. Baker LR, Ackrill P, Cattel WR, et al. Iatrogenic osteomalacia and myopathy dueto phosphate depletion. BMJ 1974; 3: 150-2
299. Cooke N, Teitelbaum S, Avioli LV. Antacid-induced osteomalacia and nephrolithiasis. Arch Intern Med 1978; 138: 1007-9
300. Millette CH, Snodgrass GL. Acute renal failure associated with chronic antacid ingestion. Am J Hosp Pharm 1981; 38 (9): 1352-5
301. Malek RS, Kelalis PP. Pediatric nephrolithiasis. J Urol 1975; 113: 545-51
302. Howard SC, Kaplan SD, Razzouk BI, et al. Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Leukemia 2003; 17 (3): 541-6
303. Kamitsuka MD, Williams MA, Nyberg DA, et al. Renal calcification: a complication of dexamethasone therapy in preterm infants with bronchopulmonary dysplasia. J Perinatal 1995; 15 (5): 359-63
304. Kumar N, Khwaja GA, Gupta M, et al. Antiepileptic drug induced osteomalacic myopathy with hyperparathyroidism and nephrolithiasis. J Assoc Physicians India 1993; 41 (11): 748-9
305. Urivetzky M, Kessaris D, Smith AD. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147: 1215-8
306. Smith LH. Risk of oxalate stone from large doses of vitamin C [letter]. N Engl J Med 1978; 298: 856
307. Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest 1998; 28 (9): 695-700
308. Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003; 170 (2 Pt 1): 397-401
309. Chalmers AH, Cowley DM, Brown JM. A possible etiological role for ascorbate in calculi formation. Clin Chem 1986; 32 (2): 333-6
310. Curhan GC, Willett WC, Rimm EB, et al. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 1996; 155: 1847-51
311. Curhan GC, Willen WC, Speizer FE, et al. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 1999; 10 (4): 840-5
312. Moesch C, Rincé M, Daudon M, et al. Renal intratubular crystallization of calcium oxalate and naftidrofuryl oxalate. Lancet 1991; 338: 1219-20
313. Moesch C, Charmes JP, Bouthier F, et al. Calcium oxalate crystalluria in elderly patients and treatment with naftidrofuryl oxalate. Age Ageing 1995; 24 (6): 464-7
314. Retornaz F, Jean-Pastor MJ, Monestier S, et al. Recurrent calcium oxalate nephrolithiasis induced by naftidrofuryl oxalate [letter]. Nephron 2000; 85 (1): 92
315. Van der Niepen P, Janssen van Doom K, Van den Houte K, et al. Nimesulide and acute renal failure caused by oxalate precipitation. Nephrol Dial Transplant 2002; 17: 315-22
316. Thomas DW, Edwards JB, Gilligan JE, et al. Complications following intravenous administration of solutions containing xylitol. Med J Aust 1972; 1: 1238-46
317. Evans GW, Philips G, Mukherjee TM, et al. Identification of crystals deposited in brain and kidney after xylitol administration by biochemical, histochemical, and electron diffraction methods. J Clin Path 1973; 26: 32-6
318. Dolp R, Paulini K. Oxalate formation by polytraumatized patients after parenteral nutrition with amino acids and xylitol [in German]. Int Z Vitam Ernahrungsforsch Beih 1976; 15: 228-33
319. Ludwig B, Schindler E, Bohl J, et al. Reno-cerebral oxalosis induced by xylitol. Neuroradiology 1984; 26: 517-21
320. Frydl V. Cerebrorenal oxalate formation: a metabolic abnormality following parenteral infusions of carbohydrate exchange substances [in German]. Zentralbl Allg Pathol 1987; 133 (4): 369-76
321. Dick WH, Lingeman JE, Preminger GM, et al. Laxative abuse as a cause for ammonium urate renal calculi. J Urol 1990; 143 (2): 244-7
322. Soble JJ, Hamilton BD, Streem SB. Ammonium acid urate calculi: a reevaluation of risk factors. J Urol 1999; 161 (3): 869-73
323. Navas P, Grasset D. Anurie par lithiase urétérale urique bilatérale au cours d'un traitement par l'Amplivix. J Urol Néphrol 1973; 79: 466-9
324. Matzkies F. Wirkungen und Nebenwirkungen von Benzbromaron bei der Initialbehandlung von Hyperurikämie und Gicht. Ergebnisse eines Feldversuches mit 3899 Patienten. Fortschr Med 1978; 96 (32): 1619-21
325. McLain DA, Garriga FJ, Kantor OS. Adverse reactions associated with ticrynafen use. JAMA 1980; 243 (8): 763-4
326. Paddack GL, Wahl RC, Holman RE, et al. Acute renal failure associated with ticrynafen. JAMA 1980; 243 (8): 764-5
327. Richard O, Toupance O, Hublot C, et al. Factors affecting urinary lithogenesis following tienilic acid administration in man [in French]. Therapie 1981; 36 (4): 429-34
328. Pfister B, Imhof P, Wirz H. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers. Eur J Clin Pharmacol 1978; 13 (4): 263-5
329. Hricik DE, Goldsmith GH. Uric acid nephrolithiasis and acute renal failure secondary to streptozotocin nephrotoxicity. Am J Med 1988; 84 (1): 153-6
330. Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 2001; 3 (1): 29-35